Legend Biotech (LEG) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q4 2025 revenue reached $306 million, a 64% increase year-over-year.

Gross Margin: Maintained a strong gross margin of 61%, with CARVYKTI net product sales gross margin at 57%.

Operating Margin: Improved significantly from -142% in Q2 2023 to -6% in Q4 2025.

Adjusted Net Income: Reported positive adjusted net income of $2.5 million, a turnaround from a $59 million adjusted net loss a year ago.

Cash Position: Ended the year with $949 million in cash and equivalents, providing financial flexibility for growth initiatives.

2Strategic Updates and Business Highlights

CARVYKTI Performance:

Net trade sales for CARVYKTI were approximately $555 million in Q4, a 66% year-over-year increase.

The therapy has been administered to over 10,000 patients globally and is now available in 14 markets.

The company achieved CARVYKTI profitability in 2025 and aims for company-wide profitability in 2026.

Manufacturing Capacity: Expanded capacity to support annual production of 10,000 doses, with plans to increase to 20,000 doses.

Pipeline Development: Continued focus on advancing R&D, including in vivo CAR-T programs and potential IND filings by year-end.

Market Positioning: Emphasis on earlier-line treatment adoption, with 65% of CARVYKTI patients coming from the second to fourth line settings.

3Forward Guidance and Outlook

2026 Expectations: The company anticipates CARVYKTI revenue growth of approximately 50% year-over-year, with ongoing sequential growth throughout the year.

Profitability Goals: On track for company-wide profitability in 2026, supported by disciplined expense management and revenue growth.

4Challenges and Points of Concern

Competitive Pressures: The market remains competitive with emerging therapies, including bispecifics, which may impact CARVYKTI's market share in earlier lines.

Adoption Rates: Despite growth, CAR-T therapies are still underpenetrated in earlier lines, with less than 5% of patients in the second to fourth line treated with BCMA-targeting agents.

Regulatory Landscape: The FDA's standard review of competing therapies may affect market dynamics, and the company is preparing for potential competitive entries.

5Notable Q&A Insights

Growth Strategy: Management expressed confidence in achieving sequential growth in 2026, with a focus on expanding CARVYKTI's use in earlier treatment lines.

Business Development: Interest in acquiring complementary technologies and partnerships to enhance their pipeline and market position.

Community Adoption: Expansion into community hospitals is progressing, with educational efforts to improve physician understanding of CARVYKTI's benefits.

Clinical Data: Anticipation of presenting clinical data for in vivo CAR-T programs in mid-2026, with ongoing studies to mitigate neurotoxic events associated with CAR-T therapies. Overall, Legend Biotech is positioned for significant growth driven by CARVYKTI's performance and strategic initiatives, although it faces competitive pressures and challenges in market penetration.